First New York Securities’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

First New York Securities’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$14.3K	Sell	3,500 -1,810	-34%	-$7.51K	0.03%	64
2016 Q3	$19.9K	Buy	+5,310	New	+$19.3K	0.01%	170
2015 Q2	–	Sell	-19,100	Closed	-$346K	–	624
2015 Q1	$346K	Buy	+19,100	New	+$430K	0.34%	40
2014 Q4	–	Sell	-3,056	Closed	-$74K	–	662
2014 Q3	$74K	Buy	+3,056	New	+$79.5K	0.05%	213
2014 Q2	–	Sell	-5,000	Closed	-$170K	–	494
2014 Q1	$170K	Buy	+5,000	New	+$171K	0.08%	160

Other funds holding CTIC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

First New York Securities's CTIC Position: Q4 2016 in Review

First New York Securities reduced its CTI BioPharma Corp. (DE) Common Stock (CTIC) stake by 34% in Q4 2016, selling an estimated $7.51K and leaving 3,500 shares worth $14.3K. The position accounts for 0.03% of the portfolio, ranked #64.

First New York Securities first reported a position in CTIC in Q1 2014 and has held it in 5 quarters since. The position peaked at $346K in Q1 2015. 58 funds tracked by Wall St. Rank hold CTIC as of Q4 2016.

First New York Securities held 3,500 shares of CTI BioPharma Corp. (DE) Common Stock worth $14.3K as of Q4 2016.
First New York Securities sold 1,810 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2016, an estimated $7.51K.
CTI BioPharma Corp. (DE) Common Stock made up 0.03% of First New York Securities's portfolio in Q4 2016, its #64 holding.
First New York Securities first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2014 and has held it in 5 quarters since.
First New York Securities's CTI BioPharma Corp. (DE) Common Stock position peaked at $346K in Q1 2015.
58 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2016.

Based on First New York Securities's 13F filing for Q4 2016, filed 7 Feb 2017.